TABLE 2.

Minor allele frequencies (MAFs) and p-values for Hardy–Weinberg equilibrium (P_HWE) for the three SNPs in the studies included in the meta-analysis.

Cohort	MAF rs8192678 (G482S)	PHWE rs8192678 (G482S)	MAF rs7672915 (intron 2)	PHWE rs7672915 (intron 2)	MAF rs3755863 (T528T)	PHWE rs3755863 (T528T)
AGNES	0.331	0.106	0.404 a	0.842 a	0.395	0.550
ANGNES	0.316	0.075	0.385	0.265	0.343	0.280
CDCS	0.345	0.880	0.465	0.254	0.402	0.741
CTMM	0.345	0.720	0.430	0.242	0.402	0.237
FINCAVAS	0.320	0.261	0.355	0.0006 b	0.350	0.162
GoDARTSprevalent	0.348	0.784	0.466	0.485	0.409	0.572
GoDARTSincident	0.325	0.523	0.444	0.064	0.382	0.416
IATVB	0.360	0.909	-	-	0.441 a	0.672 a
LIFE-Heart	0.323	0.135	0.432	0.950	0.367	0.109
LURIC	0.345	0.776	0.448	0.571	0.395	0.654
OHGS	0.287	0.806	0.424 a	0.215 a	0.355	0.097
PLATO	0.325	0.698	0.451	0.374	0.374	0.701
PMI	0.348	0.015 b	0.435	0.093	0.404	0.032
PROSPER	0.338	0.582	0.442	0.510	0.399	0.420
SHEEP	0.339	0.946	0.399	0.804	0.391	0.416
SMART	0.339	0.965	-	-	-	-
STABILITY	0.334	0.778	0.463	0.026 b	0.385	0.714
UCP	0.353	0.734	0.435	0.434	0.411 a	1.0 a
UKB	0.342	0.982	0.061	0.909	0.005	0.846
VIVIT	-	-	-	-	0.477 a	0.270 a
GENEBANK	0.348	0.716	0.423	0.472	0.4	0.931
INVEST	0.301	0.034 b	0.498	0.554	0.374	0.385
UCORBIO	0.337	0.643	-	-	-	-
Additional studies are not included in primary outcome analysis but included in secondary outcome analyses of all-cause mortality.
COROGENE	0.322	0.373	0.333	0.162	0.350	0.609
MDCS	0.342	0.325	0.379	0.536	0.392	0.769
TRIUMPH	0.370	0.002 b	0.464	0.103	0.404	0.015 b
WTCCC (BHF)	0.333	0.341	0.460	1.0	0.408	1.0

^aIndicates the use of a highly correlated proxy (AGNES, rs9996943; OHGS, rs7683406; IATVB, rs10938963; UCP, rs1873532; and VIVIT, rs12650562).

^bStudies with p H_WE<0.05 were excluded in sensitivity analyses for the primary outcome.